On Sep 16, 2021 Amolyt Pharma closed a Series B round and raised $80,000,000 from Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Entreprises, Eurazeo, Kurma Partners, Life Sciences Partners, Mass General Brigham Ventures, Novo Ventures, OrbiMed, Pontifax, Sectoral Asset Management, Sham Innovation Santé, featuring lead investors Andera Partners, Sectoral Asset Management.

About the company: Amolyt Pharma is located at France, Europe.
“We are building on our team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.”

Company website: http://www.amolytpharma.com